department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Renvela · pharmadog

pharmadog
drugs
Renvela

drug

patient view →

Renvela

Marketedupdated 2mo ago

by Sanofi-Aventis US LLC

Approved

community read0 votes

all catalysts(1)

approval · 1

SEVELAMER CARBONATE — FDA approval

News(0)

no news has mentioned this drug yet

brand

Renvela

generic

sevelamer carbonate

indication

Hyperphosphatemia In Chronic Kidney Disease

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 12m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Dec 6, 2030

~4.4 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (2)

Dec 6, 2030formulationUS 90955094.4y
Dec 6, 2030formulationUS 90955094.4y

🐶 often sniffed alongside

top 4

tagApproval2 co-mentions · 1 sources
drugSEVELAMER CARBONATE1 co-mentions · 1 sources
companyNavinta LLC1 co-mentions · 1 sources
tagSmall Molecule1 co-mentions · 1 sources

Trials studying Renvela

phase3AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemiacompletedn=474
phase3FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Diseasecompletedn=98
phase2Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemiarecruitingn=50
phase4Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binderscompletedn=44
phase3Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysiscompletedn=239
phase2A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patientscompletedn=55
phase3A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysiscompletedn=1,559